Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| Lucerastat | Lucerastat, the galactose form of Miglustat, is an orally-available inhibitor of glucosylceramide synthase (GCS). Lucerastat has the potential for Fabry disease study [1] [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: NB-DGJ; N-(n-Butyl)deoxygalactonojirimycin. CAS No. 141206-42-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-106392. |  |
| N- (n-Butyl ) deoxygalactono jirimycin | An extremely potent and selective a-D-galactosidase inhibitor. A selective inhibitior of GlcCer synthesis. Group: Biochemicals. Alternative Names: (2R,3S,4R,5S)-1-Butyl-2-(hydroxymethyl)-3,4,5-piperidinetriol; NBDGJ. Grades: Highly Purified. CAS No. 141206-42-0. Pack Sizes: 5mg. Molecular Formula: C??H??NO?, Molecular Weight: 219.28. US Biological Life Sciences. |  Worldwide |
| N-(n-Butyl)deoxygalactonojirimycin | Lucerastat is a selective α-D-galactosidase inhibitor. It can prevent glucosylceramide biosynthesis both in vitro and in mouse models of lysosome storage disorders through inhibiting the ceramide-specific glucosyltransferase, UDP-glucose ceramide glucosyltransferase (IC50 = 41.4 μM) but it does not affect α-glucosidase I and II or β-glucocerebrosidase (IC50s > 1 mM). In Jul 2016, Actelion completed phase Ib trial in Fabry's disease,but no development was reported for the treatment of Lipid metabolism disorders. Uses: Lipid storage disorders and fabry's disease. Synonyms: N-Butyl-1,5-dideoxy-1,5-imino-D-galactitol. Grades: 95%. CAS No. 141206-42-0. Molecular formula: C10H21NO4. Mole weight: 219.28. |  |
Our database is helping our users find suppliers everyday.
